Sivia Capital Partners LLC Acquires 176 Shares of Amgen Inc. (NASDAQ:AMGN)

Sivia Capital Partners LLC raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 16.6% in the 2nd quarter, Holdings Channel reports. The firm owned 1,234 shares of the medical research company’s stock after purchasing an additional 176 shares during the quarter. Sivia Capital Partners LLC’s holdings in Amgen were worth $385,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Aveo Capital Partners LLC increased its position in Amgen by 19.9% during the 4th quarter. Aveo Capital Partners LLC now owns 2,729 shares of the medical research company’s stock valued at $786,000 after purchasing an additional 453 shares during the period. Gryphon Financial Partners LLC boosted its stake in shares of Amgen by 295.3% in the 4th quarter. Gryphon Financial Partners LLC now owns 3,684 shares of the medical research company’s stock valued at $1,021,000 after purchasing an additional 2,752 shares during the last quarter. Principal Securities Inc. acquired a new stake in shares of Amgen during the fourth quarter worth $2,866,000. Calton & Associates Inc. bought a new position in Amgen during the fourth quarter worth $251,000. Finally, Thompson Siegel & Walmsley LLC lifted its holdings in Amgen by 121.4% in the fourth quarter. Thompson Siegel & Walmsley LLC now owns 25,893 shares of the medical research company’s stock valued at $7,458,000 after buying an additional 14,200 shares during the period. 76.50% of the stock is owned by institutional investors.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $320.56 on Friday. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26. The firm’s 50-day simple moving average is $326.26 and its 200 day simple moving average is $302.12. The stock has a market cap of $171.96 billion, a price-to-earnings ratio of 45.79, a PEG ratio of 2.96 and a beta of 0.58. Amgen Inc. has a fifty-two week low of $249.70 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a net margin of 10.12% and a return on equity of 161.72%. The company had revenue of $8.39 billion during the quarter, compared to the consensus estimate of $8.35 billion. During the same quarter in the prior year, the business earned $5.00 EPS. The firm’s revenue for the quarter was up 20.1% compared to the same quarter last year. As a group, research analysts anticipate that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 2.81%. The ex-dividend date was Friday, August 16th. Amgen’s dividend payout ratio is 128.57%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on AMGN. TD Cowen increased their price target on Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $305.00 target price (down previously from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. Jefferies Financial Group reissued a “buy” rating and issued a $380.00 price target (up from $375.00) on shares of Amgen in a research note on Wednesday, August 7th. Morgan Stanley reduced their price objective on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research report on Thursday, July 11th. Finally, Argus boosted their target price on shares of Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Eleven equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, Amgen has an average rating of “Moderate Buy” and a consensus target price of $327.28.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.